Publikationen 2025
TIGIT-expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D P. C. Chen, K. Deterding, S. A. Engelskircher, K. Port, L. Sandmann, A. Chakkadath, et al. Hepatology 2025 Accession Number: 39847437 DOI: 10.1097/hep.0000000000001238
Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta P. Lampertico, P. O. Bogomolov, V. Chulanov, T. Stepanova, V. Morozov, L. Allweiss, et al. Liver Int 2025 Vol. 45 Issue 2 Pages e70008 Accession Number: 39853842 PMCID: PMC11760647 DOI: 10.1111/liv.70008
Value and Kinetics of Virological Markers in the Natural Course of Chronic Hepatitis D Virus Infection L. Sandmann, V. Ohlendorf, A. Ehrenbauer, B. Bremer, A. R. M. Kraft, M. Cornberg, et al. Liver Int 2025 Vol. 45 Issue 2 Pages e70003 Accession Number: 39846714 PMCID: PMC11756344 DOI: 10.1111/liv.70003
Publikationen 2024
The Challenge of Anticoagulation in Liver Cirrhosis. Eichholz JC, Wedemeyer H, Maasoumy B. Visc Med. 2024 Jan;39(6):169-176. doi: 10.1159/000535438. Epub 2023 Dec 21. PMID: 38205270; PMCID: PMC10775854.
Genetic determinants of host- and virus-derived insertions for hepatitis E virus replication. WiĂing, M. H., T. L. Meister, M. K. Nocke, A. Gömer, M. Masovic, L. Knegendorf, Y. BrĂŒggemann, V. Bader, A. Siddharta, C. T. Bock, A. Ploss, S. P. Kenney, K. F. Winklhofer, P. Behrendt, H. Wedemeyer, E. Steinmann, and D. Todt. 2024. Nat Commun 15: 4855.
Management of chronic viral hepatitis B and D. Dietz-Fricke, C., and H. Wedemeyer. 2024. Clin Liver Dis (Hoboken) 23: e0221.
Hepatitis D virus – still the devil ! A. Wranke and H. Wedemeyer Hepatology 2024 Accession Number: 39471056 DOI: 10.1097/hep.0000000000001144
Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies P. Lampertico, M. P. Anolli, D. Roulot and H. Wedemeyer Gut 2024 Accession Number: 39663120 DOI: 10.1136/gutjnl-2024-332597
[Significant increase in newly diagnosed hepatitis B and C cases in Germany due to screening] D. HĂŒppe, Y. Serfert, M. Cornberg and H. Wedemeyer Z Gastroenterol 2024 Accession Number: 39586812 DOI: 10.1055/a-2435-5069
Publikationen 2023Â
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Schulze Zur Wiesch J, Zeuzem S, Ciesek S, Cornberg M, Lampertico P; MYR 301 Study Group. N Engl J Med. 2023 Jul 6;389(1):22-32. doi: 10.1056/NEJMoa2213429. Epub 2023 Jun 22. PMID: 37345876.
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA. Deterding K, Xu C, Port K, Dietz-Fricke C, Xun J, Maasoumy B, Cornberg M, Wedemeyer H. J Viral Hepat. 2023 Jul;30(7):597-606. doi: 10.1111/jvh.13831. Epub 2023 Mar 28. PMID: 36924318.
Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection. Wranke A, Heidrich B, Deterding K, Hupa-Breier KL, Kirschner J, Bremer B, Cornberg M, Wedemeyer H. Hepatol Int. 2023 Dec;17(6):1359-1367. doi: 10.1007/s12072-023-10575-0. Epub 2023 Oct 3. PMID: 37789170; PMCID: PMC10661878.
HDV RNA assays: Performance characteristics, clinical utility, and challenges. Wedemeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor H, Kessler HH, Lenz O, LĂŒtgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, Miller V, Terrault N, Lampertico P; HDV RNA Assays Writing Group at the HBV Forum. Hepatology. 2023 Aug 28. doi: 10.1097/HEP.0000000000000584. Epub ahead of print. PMID: 37640384.
Interferon-based treatment of chronic hepatitis D. Sandmann L, Wedemeyer H. Liver Int. 2023 Aug;43 Suppl 1:69-79. doi: 10.1111/liv.15410. Epub 2022 Sep 2. PMID: 36002390.
Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients. Sandmann L, Deterding K, Bremer B, Port K, Cornberg M, Wedemeyer H, Maasoumy B. J Viral Hepat. 2023 Apr;30(4):283-286. doi: 10.1111/jvh.13804. Epub 2023 Jan 23. PMID: 36648369.
Treating hepatitis D with bulevirtide â Real-world experience from 114 patients. Dietz-Fricke C, Tacke F, Zöllner C, Demir M, Schmidt HH, Schramm C, Willuweit K, Lange CM, Weber S, Denk G, Berg CP, Grottenthaler JM, Merle U, Olkus A, Zeuzem S, Sprinzl K, Berg T, van Bömmel F, Wiegand J, Herta T, Seufferlein T, Zizer E, Dikopoulos N, Thimme R, Neumann-Haefelin C, Galle PR, Sprinzl M, Lohse AW, Schulze Zur Wiesch J, Kempski J, Geier A, Reiter FP, Schlevogt B, Gödiker J, Hofmann WP, Buggisch P, Kahlhöfer J, Port K, Maasoumy B, Cornberg M, Wedemeyer H, Deterding K. JHEP Rep. 2023 Mar 15;5(4):100686. doi: 10.1016/j.jhepr.2023.100686. PMID: 37025462; PMCID: PMC10071092.
Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing. Stahl Y, Kabar I, Heinzow H, Maasoumy B, Bremer B, Wedemeyer H, Schmidt HH, Pietschmann T, Schlevogt B, Behrendt P. Emerg Microbes Infect. 2023 Dec;12(2):2251598. Epub 2023 Aug 31. PMID: 37649441; PMCID: PMC10512750.
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
JHEP Rep. 2023 Jun 28;5(9):100818. doi: 10.1016/j.jhepr.2023.100818. eCollection 2023 Sep.
Pietro Lampertico , Elisabetta Degasperi , Lisa Sandmann , Heiner Wedemeyer ; Delta Cure 2022 Working Group
Quality-of-life scores improve after 96âweeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial. Dinkelborg K, Kahlhöfer J, Dörge P, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, GĂŒrel S, Zeuzem S, Erhardt A, LĂŒth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP, Wedemeyer H, Deterding K; HIDIT-2 Study Team. Liver Int. 2023 Aug;43(8):1663-1676. doi: 10.1111/liv.15602. Epub 2023 May 15. PMID: 37183524.
Publikationen 2021Â
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. Bremer B, Anastasiou OE, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gurel S, Zeuzem S, Erhardt A, Luth S, Papatheodoridis GV, Radu M, Idilman R, Manns MP, Cornberg M, Yurdaydin C, Wedemeyer H. Liver Int 2021;41(2):295-299
Liver-Resident Bystander CD8 T Cells Contribute to Liver Disease Pathogenesis in Chronic Hepatitis D Virus Infection. Kefalakes H, Horgan XJ, Jung MK, Amanakis G, Kapuria D, Bolte FJ, Kleiner DE, Koh C, Heller T, Rehermann B. Liver-Resident Bystander Gastroenterology 2021;161(5):1567-1583
Publikationen 2020Â
Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. Wranke A, Hardtke S, Heidrich B, Dalekos G, Yalcin K, Tabak F, Gurel S, Cakaloglu Y, Akarca US, Lammert F, Haussinger D, Muller T, Wobse M, Manns MP, Idilman R, Cornberg M, Wedemeyer H, Yurdaydin C. J Viral Hepat 2020;27(12):1359-1368
Publikationen 2019
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gurel S, Zeuzem S, Erhardt A, Luth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP, HIDIT-II study team. Lancet Infect Dis 2019;19(3):275-286
Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. Dias J, Hengst J, Parrot T, Leeansyah E, Lunemann S, Malone DFG, Hardtke S, Strauss O, Zimmer CL, Berglin L, Schirdewahn T, Ciesek S, Marquardt N, von Hahn T, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Sandberg JK, Bjorkstrom NK. J Hepatol 2019;71(2):301-312
Hepatitis D Virus-Specific CD8 T Cells Have a Memory-Like Phenotype Associated With Viral Immune Escape in Patients With Chronic Hepatitis D Virus Infection. Kefalakes H, Koh C, Sidney J, Amanakis G, Sette A, Heller T, Rehermann B. Gastroenterology 2019;156(6):1805-1819
FrĂŒhere PublikationenÂ
The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. Schirdewahn T, Grabowski J, Sekyere SO, Bremer B, Wranke A, Lunemann S, Schlaphoff V, Kirschner J, Hardtke S, Manns MP, Cornberg M, Wedemeyer H, Suneetha PV. J Infect Dis 2017;215(1):139-149
Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP, HIDIT Study Grp. N Engl J Med 2011;364(4):322-331